CRVL — CorVel Corp
NASDAQ · Health Care · Health Care
- Latest Close
- $57.33
- 30-Day Move
- -19.0%
- Market Cap
- $2.8B
- Shares Outstanding
- 51,150,000
- P/E Ratio
- 26.35
- P/B Ratio
- 17.86
CorVel Corp
A read-only Alphactor snapshot forCorVel Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$57.33
30-Day Move
-19.0%
Market Cap
$2.8B
Shares Outstanding
51,150,000
P/E Ratio
26.35
P/B Ratio
17.86
$57.33
-19.0%last 90 delayed daily bars
90D High
$72.68
90D Low
$44.83
Avg Volume
234,403
Gross margin is running at 24.2%, which gives a quick read on operating quality before you open the full model.
Net margin is 11.2%, useful for comparing CRVL against peers in Health Care.
CRVL is down 19.0% over the last 30 trading days shown on this page.
Latest operating income is $32M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$51.34
Rule of 40
22.8%
Dark Pool Short %
50.7%
Latest Close
$57.33
30-Day Move
-19.0%
Market Cap
$2.8B
Shares Outstanding
51,150,000
P/E Ratio
26.35
P/B Ratio
17.86
ROE
29.6%
ROA
17.4%
Gross Margin
24.2%
Operating Margin
14.5%
Net Margin
11.2%
Debt / Equity
0
Current Ratio
1.9
Latest Revenue
$236M
Revenue
$236M
Gross Profit
$55M
Operating Income
$32M
Net Income
$24M
Gross Margin
2422.0%
Net Margin
1123.0%
Current Ratio
1.90
Debt / Equity
0.00
Fair Value
$51.34
Upside / Downside
-10.4%
Signal
Overvalued
Implied Growth
11.2%
DCF
$41.59
EPV
$22.11
EV/Rev
$90.33
Growth Assumption
11.5%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$92M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
12.55
Safe
Piotroski
8
Strong (7-9)
Cash Conversion
1.34x
Rule of 40
22.8%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $646M | $85M | $66M | $37M |
| 2023-12-31 | $719M | $85M | $66M | $56M |
| 2024-12-31 | $795M | $95M | $76M | $70M |
| 2025-12-31 | $896M | $121M | $95M | $92M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 1,899,031 | 0.04% | 2026-02-28 |
| Virtus Equity Trust-Virtus KAR Small-Cap Core Fund | 941,869 | 0.02% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 883,945 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 715,196 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 638,344 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 360,300 | 0.01% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 337,907 | 0.01% | 2025-12-31 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Portfolio | 332,327 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
BlackRock
Filed 2024-05-10
$382M
--
Vanguard Group
Filed 2025-05-09
$362M
-1.5%
Renaissance Technologies
Filed 2025-05-14
$205M
--
Geode Capital Management
Filed 2025-08-08
$87M
+5.3%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.